Bulletin
Investor Alert

NLS Pharmaceutics

IPO: US:NLSP

Company Description

Developing controlled-release formulations of approved drugs for ADHD and narcolepsy.

Filing Information

File Date

2/28/2020

File Shares

N/A

Low Price Range

N/A

High Price Range

N/A

Proposed Offering Amount

$40,250,000

Exchange

Nasdaq

Underwriter Information

Bookrunner

Maxim Group LLC

Bookrunner

Brookline Capital Markets

Bookrunner

N/A

At a Glance

Company

NLS Pharmaceutics

Address

City/State

Stans, Switzerland

Phone

N/A

Web

www.nlspharma.com

Industry

Health-Biotech

Employees

5

Founded

2015

Financial Information

Ltm Date

N/A

Ltm Sales

N/A

Employees

N/A

Use of Proceeds

Clinical trials, CBO Transaction Fee

IPO Discussion

MarketWatch News on NLSP

No news currently available
Link to MarketWatch's Slice.